Video: Progress in the management of EGFR-mutant NSCLC in 2020: Where are we now?*July 2020*Dr. Roy Herbst addresses this question in a video. Watch it here.DonateSupport EGFRLatest NewsletterGet Social: Twitter Tweets by @egfrresistersCategoriesAdvocacy (4)Coping With Cancer (16)Events (1)Funding (1)Research (101)Stories (4)Treatments (91)Uncategorized (1) laurabbook@gmail.com2020-09-18T16:22:19-07:00Share This Post, Choose Your Platform!FacebookTwitterLinkedInTumblrPinterest Related Posts Ask the Experts: Progression and Resistance Ask the Experts: Progression and Resistance January 21st, 2021 Enriching Responses With Targeted Therapy in NSCLC Enriching Responses With Targeted Therapy in NSCLC January 21st, 2021 Genetic Heterogeneity of MET-aberrant Non-Small Cell Lung Cancer and its Impact on the Outcome of Immunotherapy Genetic Heterogeneity of MET-aberrant Non-Small Cell Lung Cancer and its Impact on the Outcome of Immunotherapy January 21st, 2021 Increased Attention on Testing for Oncogenic Drivers in NSCLC Advances the Promise of Precision Medicine Increased Attention on Testing for Oncogenic Drivers in NSCLC Advances the Promise of Precision Medicine January 21st, 2021